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A B S T R A C T
Triamcinolone acetonide (TA) is classiﬁed as an S9 glucocorticoid in the 2014 Prohibited List published
by the World Anti-Doping Agency, which caused it to be prohibited in-competition when administered
orally, intravenously, intramuscularly or rectally. The Minimum Required Performance Level (MRPL) for
the detection and identiﬁcation of glucocorticoids is 30 ng/mL. Other common local injection routes,
such as intraarticular, intratendinous, or intrabursal injection, are not prohibited. The purpose of this
studywas to analyze the TA and triamcinolone (T) concentrations in urine after a single injection of TA in
patients to determine if it would produce a positive result. This studywas performed on 40 patients with
sports injuries or joint pains. TAwas administered locally (doses varied from 12 to 80 mg). Samples were
extracted using a solid-phase extraction column, followed by hydrolysis and liquid extraction using
diethyl ether. The elution solvents were collected and dried. The dried residue was reconstituted and
assayed by performing liquid chromatography–tandem mass spectrometry (LC–MS/MS) in positive
ionization mode using electrospray ionization and multiple-reaction monitoring as the acquisition
mode. The results demonstrated that the concentrations of both TA and T in urine exceeded the MRPL
(30 ng/mL) after a single local injection. We obtained positive results for TA in 25 patients, and a positive
result for T in one patient. Furthermore, the metabolic situation of TA, a long-acting glucocorticoid, was
not an exact linear model. The highest concentrations of TA and T appeared 1–4 h after injection. This
information could be useful for limiting the misuse of TA by athletes. We suggest that athletes be aware
when using TA injections during a competition period and obtain approval for therapeutic use
exemption prior to using TA.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Triamcinolone acetonide (TA) and triamcinolone (T) are
synthetic glucocorticoids that are widely used by athletes to treat
articular sprains, pain, and injuries [1,2]. They are both classiﬁed as
S9 glucocorticoids in the 2014 Prohibited List published by the
World Anti-Doping Agency (WADA), which prohibited the use of
these glucocorticoids in-competition when administered orally,
intravenously, intramuscularly, or rectally. The Minimum Re-
quired Performance Level (MRPL) for the detection and identiﬁca-
tion of glucocorticoids is 30 ng/mL [3].* Corresponding author. Tel.: +886 7 3121101x2793; fax: +886 73138359.
E-mail address: meichich@kmu.edu.tw (M.-C. Hsu).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.forsciint.2014.07.024
0379-0738/ 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access
sa/3.0/).Glucocorticoids inhibit systemic inﬂammation and reduce
neuropathic pain [4]. Numerous methods of administrating TA
were prescribed in Taiwan, including injection, ointment, drip,
spray, and tablets. For years athletes have frequently used TA to
treat sport-induced injuries, primarily by using local injection
routes. The dosage of a local TA injection depends on the site and
size of the articulation, inﬂammation, and the quantity of synovial
ﬂuid. The dosage of knee and shoulder joint injections ranges from
40 to 80 mg; small-joint, intratendinous, and intrabursal injections
range from 10 to 40 mg; and soft tissue injections range from 10 to
20 mg.
Previous studies [5–11] have reported the pharmacokinetics of
TA after oral, intravenous, intramuscular, and inhalation adminis-
tration, and these studies have primarily focused on investigating
the TA concentration in blood instead of urine. One study [12]
indicated that the average elimination half-lives of intravenouslyarticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-
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23.8 h, respectively, and the maximal plasma concentration of
intraarticular and intramuscular was attained at 10 and 13 h,
respectively. Additionally, previous study stated that the main
metabolite of TA in urine was 6 beta-hydroxy triamcinolone
acetonide [9], but it is not a doping substance listed in WADA.
However, after administering TA intravenously, T is one of the
metabolites of TA [6], and once it exceeded the MRPL would
offense the rule still [3].
According to the WADA, adverse results should be reported
when the concentrations of TA or T in urine are beyond the MRPL
(30 ng/mL). Administering local glucocorticosteroid injections
(such as intraarticular, intratendinous, or intrabursal injection)
in the treatment of noninfectious local inﬂammatory conditions is
commonly accepted in medical practice and provides symptom
relief and often a rapid recovery and subsequent return to sporting
activity [13]. However, whether these routes of administration
produce positive analytical results is still unclear. The purpose of
this study was to determine the possibility of obtaining positive
results by using various injection routes, and investigate the
metabolism situation between TA and T in urine after a single-dose
local injection of TA.
2. Materials and methods
2.1. Materials
Triamcinolone, triamcinolone acetonide standards, b-glucu-
ronidase, and HPLC-grade formic acid were purchased from
Sigma–Aldrich Chemical Co. (St. Louis, MO, USA). Betametha-
sone-D5 standard was obtained from C/D/N Isotopes Inc. (Quebec,
Canada). Methanol was purchased from Echo Chemical Co., Ltd.
(Miaoli, Taiwan). Acetic acid was purchased from Mallinckrodt
Pharmaceuticals (Dublin, Ireland). Reagent-grade potassium phos-
phate monobasic was obtained from Showa PK Co., Ltd. (Arakawa-
Ku, Tokyo, Japan). Diethyl ether was purchased from J.T. Baker
(Center Valley, PA, USA). Doubly deionized water was obtained
from a Millipore Direct-Q5 system (Bed ford, MA, USA) and used
throughout the study.
2.2. Instruments
The LC–MS/MS equipment consisted of an Agilent 1100 Series
(Agilent Technologies Italia SpA, Cernusco sul Naviglio, Italy) high-
performance liquid chromatograph (HPLC) with a vacuum
degasser, binary pump, and an autosampler connected to an
Applied Biosystems API 3000 triple-quadrupole mass spectrome-
ter equipped with a TurboIonSpray ionization (electrospray ion
[ESI]) source (Applied Biosystems/MDS SCIEX, Canada). Data
acquisition was performed using Analyst 1.4.2 software (Applied
Biosystems/MDS SCIEX).
2.3. Liquid chromatography–tandem mass spectrometry
Chromatographic separation was performed at room tempera-
ture using a Supelco Discovery1 HS-C18 HPLC column
(50 mm  2.1 mm, 3mm particle size; PA, USA) and a Supelco
Discovery1 HS-C18 guard column (2 cm  2.1 mm I.D., 3mm
particle size; PA, USA). A two-solvent linear gradient system
was used. Solvents A (deionized distilled water with 0.02% formic
acid) and B (methanol) were ﬁltered through a 0.45-mm
membrane and degassed before use. A linear gradient was run
at 30% solvent B, increased to 70% B from 0 to 4 min (a ﬂow rate of
0.3 mL/min), increased to 90% B from 4 to 10 min (a ﬂow rate of
0.15 mL/min), then decreased to 30% B from 10 to 10.5 min (a ﬂowrate of 0.3 mL/min), and ﬁnally reequilibrated at 30% B for 5.5 min
(a ﬂow rate of 0.3 mL/min).
The conditions were maintained at an optimal state for the
analysis of triamcinolone acetonide and triamcinolone. The turbo
gas temperature was 450 8C, and the auxiliary gas ﬂow was 8.0 L/
min. Nebulizing gas, curtain gas, and collision gas ﬂows were
regulated using the instrument settings of 13, 7, and 11 L/min,
respectively. The IonSpray voltagewas set at 5500 V. The detection
and quantiﬁcation of analytes was performed in multiple-reaction
monitoring (MRM) positive acquisition mode using ion precur-
sor! product ion combinations of m/z 435! 415/357 for TA and
395! 357/321. The collision energy used for performing MRM
transitions of TA and T was set at 15 and 17 eV, respectively.
2.4. Sample preparation
The sample preparation method was modiﬁed from that used
by Luca Amendola et al. [14]. Urine sampleswere collected from 40
Taiwanese patients. A 4 mL aliquot of urine, 1 mL of KH2PO4 buffer
(0.1 M, pH 6.0), and 50 mL of internal standard (IS) betamethasone-
D5 (5mg/mL) were mixed. The solid phase extraction columns
were washed with methanol (0.4 mL). The samples were then
poured into the columns. The samples were washed with doubly
deionized water (2.0 mL), acetic acid (2.0 mL, 0.1 M), and then
methanol (2.0 mL). The residueswere dried under nitrogen at 40 8C
and reconstituted in 1 mL of KH2PO4 buffer (0.1 M, pH 6.0). The
samples were subsequently incubated with 25mL of b-glucuroni-
dase for 1 h at 50 8C. After hydrolysis, 250mL of 7% K2CO3 solution
was added to the samples. The samples were then extracted with
5 mL of diethyl ether for 5 min. The organic phase was collected
and dried under nitrogen at 60 8C. The residues were reconstituted
in 350 mL of Solvents A and B (85:15). Finally, the samples were
ﬁltered through a 0.45-mm membrane. Aliquots of the samples
(20 mL) were injected into the LC–MS/MS system.
2.5. Method validation
Speciﬁcity was assessed by analyzing urine samples from six
sources. The specimens were prepared using the same sample
preparation and analytical procedures to identify interfering peaks
at the retention times of analytes or the IS.
Linearity was assessed using eight standard urine solutions
with concentrations ranging from 1 to 200 ng/mL. The urine
calibration curves were prepared and assayed on 6 separate days.
The peak ratios of TA and T were applied to calculate the
correlation coefﬁcient, intercept, and slope by using weighted
linear regression. A correlation coefﬁcient of0.99was considered
acceptable. The limit of detection (LOD) was deﬁned as the lowest
level of concentration at which a compound could be identiﬁed in
all the urine samples tested using the lowest transition with a
signal-to-noise ratio of 3. The limit of quantiﬁcation (LOQ) was
deﬁned as the lowest concentration on the calibration curve for
which an acceptable accuracy of 20% and a precision under 20%
were exhibited.
The acquisition segments and the relative retention times
(RRTs) of the analytes were assessed. Repeatability was estimated
using the intraday and interday coefﬁcient of variation in the RRTs,
ion ratio interday precision, and the ion ratios of the characteristic
transitions at the LOD concentration of the analytes. The intraday
precision was achieved by performing analytes (n = 6) of quality
control (QC) methanol samples on the same day.
A concentration of 30 ng/mL for each analyte was used for QC
and prepared in six replicates. The evaluation of interday precision
was conducted by performing analytes over 6 days during the
study period, and using QC samples thatwere newly prepared each
day.
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urine samples were fortiﬁed with analytes before or after sample
preparation. The recovery was calculated by comparing the mean
peak area of the samples fortiﬁed prior to and after sample
preparation.
2.6. Drug administration and urine collection
Forty patients with sports injuries or joint pains from Yuan’s
General Hospital (Kaohsiung, Taiwan), with amean age (standard
deviation [SD]) of 58.8 (11.8) years, weight of 63.8 (8.9) kg, and
height of 161.8 (8.7) cm, participated in the experiment. The study
was conducted on 29 participates by administering intratendinous
injections, three participates by administering intraarticular injec-
tions, three participates by administering intrabursal injections, four
participates by administering lumbar epidural injections, and one
participate by administering an intramuscular injection.
After administering a single dose of TA, the urine samples of the
volunteers were collected. Thirty-eight participants agreed to
collect 2–5 times of urine randomly. The other two participants
who received intratendinous injections agreed to participate in a
48-h timed urine collection. Thus, the study was divided into two
groups: random urine collection (n = 38) and timed urine
collection (n = 2). In the random urine collection, the quantity of
water intake, number of collected samples, and the time of the
collection were not limited. In the 48-h timed urine collection,
[(Fig._1)TD$FIG]
Fig. 1. LC–MS/MS multiple-reaction monitoring chromatograms of blank human urine (A
mL) (C), and betamethasone-D5 (D).blank urine was collected before the injection. Urine specimens
were collected in the intervals of 0, 0–1, 1–2, 2–3, 3–4, 4–6, 6–8, 8–
10, 10–12, 12–16, 16–20, 20–24, 24–28, 28–32, 32–36, 36–40, 40–
44, and 44–48 h after TA administration. To ensure sufﬁcient urine
ﬂow during the sampling period, 200 mL of water was ingested
after each collection period. The pH, volume, and speciﬁc gravity of
each urine specimen at room temperature were recorded, and the
samples were stored at 20 8C before preparation for chro-
matographic analysis. The study procedures were approved by the
Human Research Ethics Committee of Yuan’s General Hospital
(Kaohsiung, Taiwan).
3. Results and discussion
3.1. Method validation
The chromatograms of the urine spiked with TA, T, and blank
urine are illustrated in Fig. 1. The retention times of TA, T, and
betamethasone-D5 were 9.46, 7.23, and 10.96 min, respectively;
this is well within the acceptable range of 2%. No interfering
signals from endogenous substances were observed during the
retention times of the analytes. For the ion ratio, the acceptable range
is 20%, 29.68–44.52 and 27.84–41.76 for TA and T, respectively.
The correlation coefﬁcients (r2) of the calibration curves for TA
and T were 0.9971 and 0.9944, respectively. The mean calibration
curves for TA and T were plotted using the following equation:), urine spiked with triamcinolone acetonide (30 ng/mL) (B), triamcinolone (30 ng/
Table 1
The acquisition segment, RRT, intraday precision during the RRT (CVa), interday precision during the RRT (CVb), ion ratio interday precision (CVc), MRM transition, and
recovery for TA and T.
Analyst Acquisition
segment (min)
RRT CVa (%) CVb (%) CVc (%) CE (V) MRM transition Recovery (%)
Triamcinolone
acetonide
9–10.5 0.853 0.64 0.20 5.94 17/19 395!357/321 88
Triamcinolone 7–8 0.647 0.28 0.07 1.99 15/19 435!415/357 79
RRTs, relative retention time; CVa, intraday precision during the RRTs; CVb, interday precision during the RRTs; CVc, ion ratio interday precision.
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method exhibited favorable linearity over the concentration
ranges of 1–200 ng/mL.
Table 1 shows the acquisition segment, RRT, intraday precision
during the RRT (CVa), interday precision during the RRT (CVb), ion
ratio interday precision (CVc), MRM transition, and recovery for TA
and T. The LODwas 2 ng/mL, which was considerably less than theTable 2
Urinary triamcinolone acetonide concentration (ng/mL) following different injection of
Subject Time (h)
0–1 1–2 2–3 3–4 4–5 5–6 6–
Tendon (12mg) 1 – 13.8 – – 43.4b –
2 – 12.5 – – 11.6 –
3 – 1.2a – 12.4 – –
4 2.0a – – – 30.8b –
5 – 5.4 24.5 – – 1.3a
6 ND – 43.3b – – –
7 – 2.3a – – – 15.4
8 – – 3.7a – – –
9 – 40.4b – – 35.0b –
10 – 2.9a – 7.5 – –
11 – – – 76.2b – – 11
12 – – – 4.8a 4.9a – 1
13 – 9.3 – 7.2 16.0 26.6
Tendon (16mg) 14 – – 3.2a – – ND
Tendon (20mg) 15 – – 4.9a – 29.4 –
16 – – – – 145.7b –
Tendon (24mg) 17 42.6b – 33.8b – – –
Tendon (30mg) 18 – 10.8 – – 20.8 –
19 – 81.3b 54.6b 61.9b 35.5b –
Tendon (40mg) 20 – 33.1b – 23.7 – –
21 – – 374.2b – – 155.4b
22 ND – – – – –
23 0.6a – – 17.9 45.6b –
24 36.0b 103.3b 101.3b 101.6b 185.5b –
25 26.8 11.1 – 13.9 10.0 –
26 4.7a – 7.3 5.4 – –
27 – – 36.3b 25.7 – 33.4b
Articulation
(40mg)
28 0.2a – 20.7 – 30.2b 20.7
29 – ND – ND – –
Articulation
(80mg)
30 – 13.5 – – 20.4 –
Bursa (40mg) 31 ND 28.1 – 62.1b – –
32 – – – – 31.4b –
33 – – 17.4 – 22.9 – 3
Epidural (40mg) 34 – – 159.8b – – 180.4b
35 128.5b – 233.8b – – –
Epidural (80mg) 36 – – – – – 94.1b
37 – – 70.7b – – –
Muscle (80mg) 38 – – – 113.0b – – 9
ND: sample was not determined; –: no urine collection at the time point.
a Indicates concentration below LOQ (5ng/mL).
b A TA-positive result according to WADA’s rule (above 30ng/mL).MRPL of glucocorticoids (30 ng/mL) declared by the WADA. The
LOQ was 5 ng/mL.
Pujos et al. [15] compared the analysis of corticosteroids byusing
various techniques for applyingdoping tests, anddemonstrated that
LC–MS andGC–MSweremore sensitive and speciﬁc than ELISAwas.
Our results demonstrated that this LC–MS/MSmethodwas suitable
for the quantiﬁcation of TA and T in human urine.single-dose triamcinolone acetonide by random collection.
7 7–8 8–9 9–10 10–11 11–12 12–14 14–16 16–20
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– 4.7a – – – – – – –
– – – – – – 48.4b 49.0b –
– 11.7 – – – – 12.1 – –
– 3.6a – – – – 0.7a 3.3a –
– 22.3 – – 30.9b – – – –
4.9a – 9.6 – – – – – –
6.0b – – – – – – 84.7b 51.4b
2.9 – 11.5 – – – – – –
– – – – – – – – –
– – – 2.4a – – – – –
– – – – – – – – –
– 204.0b – – – – – 61.8b 22.7
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – 125.5b – – – – –
– 59.7b – – – – 11.2 – –
– 43.4b – – – – – – –
– – – – – – – – –
– – – – – – – – –
9.3 – – – – – – – –
– 38.8b – – – – – – –
– – – – – – – – –
– ND – – 5.3 – – – –
– – – – – – – – –
– – 27.6 – – – – – –
– – 32.0b – – – 29.3 – 25.9
7.3b – – 39.7b – – – – –
– – – – – – – – –
– – – – – – – – –
– – – 48. 9b – – – 56.7b 92.8b
– – 123.0b 55.5b – – – – –
9.0b – – – – – – – –
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The results indicated that the administration of a single dose of
triamcinolone acetonide by using both nonprohibited local routes
(intratendinous, intraarticular, and intrabursal injections) and
prohibited systemic routes (lumbar epidural and intramuscular
injections) produced positive TA and T results.
Table 2 shows the positive results of TA in the 14 (n = 27)
subjects who received intratendinous injections, one (n = 3)
subject who received an intraarticular injection, three (n = 3)
subjects who received intrabursal injections, 4 (n = 4) subjectswho
received lumbar epidural injections, and one (n = 1) subject who
received intramuscular injections in the random urine collection
group. The concentration of T in the 38 subjects belonging to the
random urine collection group ranged from 0 to 15.2 ng/mL. We
did not identify a strong relative connection between the
concentrations of TA and T when using various local injection
routes. Furthermore, one study [16] revealed that identifying a
speciﬁc marker for the use of intraarticular or intramuscular
injections was not possible.
Fig. 2 shows the urinary TA and T concentration-time proﬁles
after administering intratendinous injections of 12 mg and 20 mg
triamcinolone acetonide in two subjects from the timed collection
group. The mean urinary pH and speciﬁc gravity (mean  SD)
observed in 48 h were 6.1  0.5 and 1.017  0.009, respectively. The
time to the peak concentrations (Tmax) of TA and Twere 4 h and 2 h in
subject receiving 12 mg injection, and were 3 h and 2 h in subject
receiving 20 mg injection. The peak urine levels (Cmax) of TA and T
were 30.3 ng/mL and 22.5 ng/mL in subject receiving 12 mg injection,
and were 53.0 ng/mL and 54.5 ng/mL in subject receiving 20 mg
injection. The excretion of TA was the highest 20–36 h after
intratendinously administering a single dose of TA. The percentage
ratios of excretion-to-administration were 0.21% and 0.29% for the
[(Fig._2)TD$FIG]
Fig. 2. Urinary concentration–time proﬁle of triamcinolone acetonide (A) and
triamcinolone (B) after intra-tendinous injection of 12 and 20 mg triamcinolone
acetonide in different subjects by timed collection. Peak urine levels (Cmax) are
showed in the proﬁles.20-mg injection and 12-mg injection, respectively. However, the
excretion of T exhibited the highest amount between 1 and 4 h. The
percentage ratios of excretion-to-administration were 0.01% and
0.02% for the 20-mg injection and 12-mg injection, respectively.
Additionally, the ascending curve between 40 and 48 h in Fig. 2
indicates that TA was not excreted entirely.
Fig. 2 shows that the metabolic situation of TA, a long-acting
glucocorticoid, was not an exact linear model. In tendons, joints,
and muscles, drugs are absorbed into the bloodstream by simple
diffusion through capillaries, the smallest blood vessels in human
bodies that connect arterioles and venules. Even a single
therapeutic dose administered intraarticularly would be detect-
able in urine because of the (limited) absorption and systemic
distribution [17]. The metabolic situation revealed in the study
results was consistent with that observed in previous studies
[6,18].
This could be because achieving complete absorption from the
site of injection takes a long time because of the low solubility of TA
[18], the total body clearance is considerably different at various
times of the day [19], or the differences in ﬂuid intake and
excretion can substantially dilute urinary drug concentrations
[20].
Although T is not the main metabolite of TA [6], an analytically
small amount of T was observed in urine after TA administration,
despite exceeding 30 ng/mL. Therefore, we may possibly have
misinterpreted the legitimate TA local injection users as T oral
administration users, which would violate the WADA’s rules. TA
local injections are used widely for treating sports-related injuries.
The study results provide information for limiting themisuse of TA
by athletes.
4. Conclusion
Although local injections of glucocorticoids are not prohibited
by the WADA, the results revealed that the concentration of both
TA and T in urine can exceed the MRPL (30 ng/mL) after a single
local injection. Therefore, we suggest that athletes be cautious
when considering a TA injection during a competition period and
seek approval and exemption for TA use prior to administration.
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